Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of propafenone metaboliser phenotype from plasma and urine excretion data.

European journal of clinical pharmacology - 1 Jan 1992

Latini R, Belloni M, Bernasconi R, Cappiello E, Giani P, Landolina M, Leopaldi D, Castel J M

Abstract excerpt

The aim of the study was to validate a test based on analyses of urine to identify the propafenone metaboliser phenotype during routine chronic therapy. Twenty seven patients chronically treated with propafenone were studied. A debrisoquine test was performed in 10. Propafenone and its metabolites in plasma and urine were measured by HPLC. Propafenone, 5-hydroxypropafenone and N-depropylpropafenone concentrations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged
Share to Arrhythmias, Cardiac

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Debrisoquin

Share to Hydroxylation

Share to Phenotype

Source

Identifiers

PMID: 1541308
DOI: 10.1007/BF00314930

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of propafenone metaboliser phenotype from plasma and urine excretion data.PMID 1541308Read ↗

Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides.Semantic proximity Read ↗

Determination of oxidation phenotype by measurement of propafenone urinary metabolic ratios.Semantic proximity Read ↗

Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping.Semantic proximity Read ↗

[Determination of oxidative phenotype in a sample population and correlation with the pharmacokinetics of propafenone].Semantic proximity Read ↗

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.Semantic proximity Read ↗

Use of a propafenone metabolic ratio as a measure of CYP2D6 activity.Semantic proximity Read ↗

Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.Semantic proximity Read ↗

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.Semantic proximity Read ↗

A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.Semantic proximity Read ↗

Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.Semantic proximity Read ↗

Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.Semantic proximity Read ↗

Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.